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Patients with testicular germ cell tumours (TGCTs) have 
good prognosis due to high sensitivity to platinum-based 
chemotherapy (Voutsadakis 2014). The Surveillance, 
Epidemiology, and End Results (SEER) program (2008–2014) 
reported a 5-year survival rate of 95.3% for patients 
with all tumour stages and 73.7% for those with distant 
metastasis (Noone  et  al. 2018). However, long-term side 
effects and morbidity after chemotherapy is a problem 
in this young patient group, and therefore, research is 
essential (Oldenburg  et  al. 2007, Kraggerud  et  al. 2009). 
Young Caucasian men have the highest TGCT incidence 
(Rosen et al. 2011) with an unexplained, marked increase 
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over the last 50 years, especially in industrialized 
countries. Genome-wide association studies (GWAS) and 
large-scale meta-analyses (Chung  et  al. 2013, Rajpert-De 
Meyts et al. 2016, Litchield et al. 2017, Wang et al. 2017) 
have identiied above 40 susceptibility loci. The mutation 
load has been found to be low, comparable to paediatric 
cancer types (Brabrand et al. 2015, Litchield et al. 2015), 
but TGCTs are characterized by aneuploidy and a high 
degree of DNA copy number changes (Oosterhuis  et  al. 
1989, Lothe et al. 1995, Taylor-Weiner et al. 2016).
TGCTs can be divided into two main histological 
types, seminomas and non-seminomas, with the latter 
comprising embryonal carcinomas (ECs), teratomas, 
choriocarcinomas, and yolk sac tumours. The various 
histological subtypes of TGCT have remarkably 
similar DNA copy number aberration (CNA) patterns, 
although some particular differences have been 
described (Kraggerud  et  al. 2002, Skotheim  et  al. 2006, 
Korkola  et  al. 2008). The isochromosome 12p and/or 
gain of 12p sequences are pathognomonic to TGCT and 
used for diagnostic purposes for extragonadal tumours of 
unknown origin (Sandberg et al. 1996). Most genome-wide 
DNA copy number studies of TGCTs to date have been 
performed using relatively low-resolution technologies, 
but recently TCGA published a multilevel genomics 
paper, including next-generation sequencing and high-
resolution single nucleotide polymorphisms (SNPs) 
microarray analysis of 150 TGCTs, including 27 tumours 
classiied as EC (18 pure EC and 9 mixed) according to 
the International Classiication of Diseases for Oncology 
(ICD-O) morphological codes (Shen et al. 2018).
EC is a pluripotent histological subtype of TGCT that 
can be present alone or as one of several components 
in the tumour. ECs can be considered the malignant 
counterpart of embryonic stem (ES) cells, as both are 
pluripotent and have the capacity to differentiate. 
Identiication of molecular differences between the two 
cell types may help resolve tumourigenic mechanisms 
and cellular pathways involved. We previously identiied 
a discriminating gene expression signature between EC 
and ES cell lines, including a number of pluripotency and 
cancer-related genes (Alagaratnam et al. 2013). ES cell lines 
have been characterized for DNA CNAs on high-resolution 
SNP platforms (Närvä et al. 2010, Amps et al. 2011), where 
several higher-passage cells showed aberrations similar to 
those in TGCTs (Baker et al. 2007).
In this study, we proiled 13 pure primary EC 
tumours, as well as 12 cell lines (5 EC and 7 ES) on the 
high-resolution, whole-genome Affymetrix SNP 6.0 DNA 
copy number platform. We present a comprehensive 
overview of the EC subtype, identifying recurring regions 
of loss of heterozygosity (LOH) and focal regions of 
gains and losses, which harbour genes that may be of 
importance in EC development. These genes were further 
investigated in publically available multi-omics datasets 
and a transcriptional impact was conirmed for several of 
the genes.
0DWHULDOVDQGPHWKRGV
6DPSOHSUHSDUDWLRQV
Genomic DNA from 13 primary ECs had previously 
been isolated by phenol/chloroform extraction. Tumour 
percentage was estimated by an experienced pathologist 
on the basis of haematoxylin and eosin stained sections 
for 10/13 samples. For each case, the tumour percentage 
was calculated as the average of the tumour percentage of 
three sections, taken at either end and in the middle of 
the tumour sample used for DNA isolation. The median 
pathology tumour percentage was 49%, and ranged 
from 22% to 78%. Ten of the 13 primary ECs included 
in the current study have previously been analysed by 
chromosomal comparative genomic hybridization (cCGH; 
n = 6, Kraggerud et al. 2002) and array CGH (aCGH; n = 5, 
Skotheim  et  al. 2006), with one sample (EC no. 1838) 
analysed with both technologies.
Genomic DNA was isolated from ive EC cell lines 
(NTERA2, 2102Ep, 833KE, TERA1, and NCCIT) and 
seven early-passage (<50 passages) ES cell lines (Shef3, 
Shef4, Shef6, Shef7, H7, H9, and H14 using the AllPrep 
DNA/RNA Mini kit (Qiagen). All cell lines were cultured, 
sorted by the SSEA3-antigen, and ingerprinted by 
analysis of short tandem repeats as previously described 
(Alagaratnam et al. 2013).
'1$FRS\QXPEHUSURȴOLQJRISULPDU\WXPRXUVDQG
FHOOOLQHV
Three sets of samples were analysed for genome-wide 
DNA copy number on Affymetrix SNP 6.0 microarrays: 
primary EC tumours (n = 13), EC cell lines (n = 5), and ES 
cell lines (n = 7). For each sample, 500 ng of genomic DNA 
was used as input for the Cytogenetics Copy Number 
Assay protocol for Genome-Wide Human SNP 6.0 arrays 
(Thermo Fisher Scientiic). The samples were individually 
processed and hybridized as described in the Affymetrix 
Cytogenetics Copy Number Assay User Guide (P/N 
702607 Rev. 2).
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'DWDSURFHVVLQJWDUJHWUHJLRQDQDO\VLVDQGVWDWLVWLFV
The resulting cell intensity (CEL) iles after hybridization 
were within recommended QC thresholds (CQC >0.4; 
MAPD <0.35). Signal extraction and pre-processing 
of the raw data was performed using the PennCNV 
protocol modiied for Affymetrix genotyping arrays with 
Affymetrix Power Tools version 1.15.0 as described earlier 
(Sveen et al. 2016). HapMap samples previously analysed 
on the SNP Array 6.0 (n = 270), were used as reference for 
normalization, log R ratio (LRR), and B-allele frequency 
(BAF) calculation. Probes targeting the allosomes, control 
probes (n = 3643), duplicate probes (one of the two probes 
covering overlapping genomic loci (n = 187), and probes 
mapping to regions with recurrent high frequency 
aberrations in non-cancer samples from several organs 
(n = 6668) were removed (Sveen et al. 2016).
For copy number analysis, preprocessed LRR data 
results from primary tumours and cell lines were used 
for single-sample segmentation, using the Piecewise 
Constant Fitting (PCF) algorithm in the R package 
copynumber (version 1.14.0). The user-deined penalty 
parameter γ was set to 100 and the minimum number of 
probes per segment, kmin was set to 5. PCF segments with 
copy number estimates ≥0.15 were called as gains and 
segments with estimates ≤−0.15 were called as losses. The 
results were visualized using the copynumber R package. 
In addition, CNAs (gains, ampliications (deined as high 
gains >0.45), and deletions) were extracted for 27 target 
genes, earlier identiied by our group as differentially 
expressed in EC vs ES (Alagaratnam et al. 2013).
For genomic identiication of signiicant cancer 
related regions/genes, PCF segmented data for the primary 
ECs was used as input for the GISTIC 2.0.22 algorithm 
(Mermel  et  al. 2011). Copy number estimates >0.1 were 
called as copy number gain, while estimates <−0.1 
were called as loss. The broad length cut-off was set to 
0.5 (−brlen 0.5), the conidence level was set to 0.90 
(−conf 0.90), normal arbitrated peel-off was performed 
(−armpeel 0), and we calculated the signiicance of 
deletions at a gene level (−genegistic 1), otherwise default 
settings. The reference genome ile hg19.mat was used. 
Signiicant broad events were deined as events with a 
q-value <0.05, and signiicant focal events as events with 
q-values <0.25.
Preprocessed and normalized LRR and BAF data 
for the primary ECs was analysed using the allele-
speciic copy number analysis of tumours (ASCAT) v.2.3 
algorithm to obtain allele-speciic copy number estimates 
(Van Loo  et  al. 2010). ASCAT data were subsequently 
used to call regions with ampliications and LOH. 
However, as blood/germline DNA was not analysed, the 
LOH regions may include germline homozygous regions. 
By ASCAT, we also estimated ploidy and aberrant cell 
fraction of each tumour. The penalty parameter was set 
to 50 and discrete copy number states were determined 
relative to the median genome-wide copy number in each 
tumour sample.
The fraction of the genome with CNA or LOH was 
calculated as the number of aberrant bases out of the total 
number of bases with copy number and LOH estimate 
available, respectively.
Copy number estimates per gene were retrieved by 
mapping chromosomal segments from each sample to the 
R implemented transcript database TxDb.Hsapiens.UCSC.
hg19.knownGene (v3.2.2) (Carlson et al. 2015), utilizing 
the indOverlaps function from the GenomicRanges R 
package (v1.28.3) (Lawrence  et  al. 2013). Gene symbols 
were collected using the R package org.Hs.eg.db (Carlson 
2017) and updated to the approved symbols according 
to HUGO Gene Nomenclature Committee. For GISTIC, 
the output contains the genes located in the identiied 
focal regions. However, to obtain a inal target gene list, 
the regions identiied with focal CNAs by GISTIC, were 
also manually examined for protein coding genes in 
Ensembl (Version 87, GRCh37) and these were added 
to the list of target genes. All genomic positions refer to 
genome version GRCh37 (hg19). Pseudogenes and genes 
annotated as non-coding in Ensembl were not considered.
Analysis of DNA and RNA level data from TCGA are 
described in the Supplementary Materials and methods 
(see section on supplementary materials given at the end 
of this article).
5HVXOWV
'1$FRS\QXPEHUDEHUUDWLRQVLQSULPDU\(&V
FRPSDUHGWR(&DQG(6FHOOOLQHV
By use of PCF segmentation, we identiied similar CNAs 
in primary ECs and EC cell lines (Fig. 1). In general, 
the frequencies of CNAs were higher for EC cell lines 
than for primary EC tumours. The most frequent 
aberrations observed for primary ECs were gain of 12p 
(100% of the samples) and gains of the whole or parts 
of chromosomes 7, 8, and 17 and losses of the whole or 
parts of chromosomes 4, 10, 11, 15, and 18 (>30%). From 
the PCF segmented data, apart from gain of 12p, the two 
most frequent aberrations were a region of gain at 7p21 
(12,327,848–14,412,764) and a region of loss at 10q11-q21 
(47,757,274–68,156,269). The 7p21 region, gained in 
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8/13 (>60%) ECs, contains only ive genes (ARL4A, 
DGKB, ETV1, SCIN, and VWDE), whereas the region at 
10q11-q21, lost in 6/13 (>45%) ECs, contains 81 genes 
(Table 1). Among the affected genes, ETV1, CCDC6, and 
NCOA4 are causally implicated in cancer according to the 
Cancer Gene Census (Tate et al. 2019).
From the individual tumour CNA plots 
(Supplementary Fig. 1), we observed that the 13 primary 
ECs varied markedly in both number of gains and losses 
and the proportion of the genome affected by CNAs. The 
aberrations were typically broad events of chromosome 
arm-length, and median genome wide CNA for the 
13 EC samples was 12% (mean 23%; Supplementary 
Fig. 1). Three samples (EC 28, EC 1740, and EC 1838) 
had only nine percent genome wide CNA, whereas 
the two samples with the highest percent of aberrations 
(EC 1017 and EC 3113) had 53 and 56% genome 
wide CNA.
We observed ive recurrent, CNA regions in the seven 
early passage ES cell lines (Fig. 1 and Table 2), including 
focal loss in regions 1q21.3 and 3q22.1 (both in two ES 
cell lines). These regions overlap with larger segments of 
loss also found in primary ECs (Table 1) and covers the 
genes LCE1E and ALG1L2, respectively.
)LJXUHb
'1$FRS\QXPEHUDEHUUDWLRQIUHTXHQF\
)UHTXHQF\SORWVVKRZLQJJDLQUHGDQGORVVEOXH
LGHQWLȴHGIURP3&)VHJPHQWVDQGGDWDDUH
SORWWHGDORQJFKURPRVRPHVWR$SULPDU\
ECs (nɋ ɋZLWKWKHWZRPRVWIUHTXHQW&1$V
DSDUWIURPWKHXELTXLWRXVSDPSOLȴFDWLRQ
LQGLFDWHG%(&FHOOOLQHVnɋ ɋDQG&(6FHOO
lines (nɋ ɋ ?Q'IUHTXHQFLHVRI/2+DPRQJWKH
primary ECs and the genes located in the regions 
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6LJQLȴFDQW'1$FRS\QXPEHUHYHQWVLQSULPDU\(&V
PCF-segmented data from the 13 primary ECs were 
analysed with GISTIC to identify statistically signiicant 
CNAs, both in terms of chromosome arm-level (broad; 
Supplementary Table 1) and focal events. We identiied 
three signiicant focal regions of gain, located at 12p13.31, 
12p11.1, and 22q11.23; and ive signiicant focal regions 
of loss, located at 1p36.11, 1q21.3, 3q22.1, 11q11, and 
17p11.2 (Table 1 and Supplementary Fig. 2). Although 
the 1q21.3 and 3q22.1 segments covers the LCE1E and 
ALG1L2 genes, also found to be lost in ES cell lines, they 
were not excluded from further analyses.
3ORLG\DOOHOHVSHFLȴFFRS\QXPEHUSURȴOHVDQG/2+
LQSULPDU\(&V
Ploidy estimates for the 13 tumours, as calculated by 
the ASCAT algorithm, ranged from 2.3 to 5.0. The 
ploidy values formed two clusters, one between 2.3 and 
2.8 (9/13 tumours) and one between 4.4 and 5.0 (4/13 
tumours; Supplementary Fig. 3). Individual allele-
speciic proiles of the 13 tumours are shown in 
Supplementary Fig. 4.
The ASCAT analysis revealed a minimal amplicon of 
100 kbp (chr12: 8,024,362–8,123,900) that was present at 
15 and 31 additional copies in two individual tumours 
and gained across all 13 tumours (Fig. 2). For 12/13 ECs, 
this amplicon was the segment, or was included within 
the 12p segment, with the overall highest copy number. 
This segment contains the SLC2A3 gene and parts of 
SLC2A14.
LOH was determined from the allele-speciic copy 
number proiles for the primary ECs (Fig. 1). The fraction 
of the genome with LOH varied from 15 to 42%, with a 
median of 26%. LOH was detected in one or more samples 
for all the autosomal chromosomes, and encompassed 
larger regions for 6 of 13 ECs on chromosome arms 4q, 
9q, 18p, and 18q. Within these broad regions of LOH, 
four additional focal regions of LOH were detected 
7DEOHɅ)RFDODEHUUDWLRQHYHQWVLGHQWLȴHGLQSULPDU\(&V
CNA type Analysis Cytoband Start ES End ES Segment size ES Genes in region
Gain 3&) S    ARL4A, DGKB, ETV1, SCIN, VWDE  
(ETV1LQ&260 ?&FDQFHUJHQHFHQVXV
Gain GISTIC 12p13.31    SLC2A3, SLC2A14
Gain GISTIC 12p11.1    -
Gain GISTIC T   25,910,952  LRP5L
Loss GISTIC 1p36.11    RSRP1a, RHD, TMEM50Aa
Loss GISTIC T    LCE1D, LCE1EE, LCE1F
Loss GISTIC T   123,922 ALG1L2E, TRHa
Loss 3&) T    JHQHVLQFOXGLQJ&260 ?&FDQFHU
genes: CCDC6 and NCOA4
Loss GISTIC T  55,363,341   OR4C6, OR4C11, OR4P4, OR4S2
Loss GISTIC S   44,194 LGALS9Ca
5HJLRQVRIJDLQDQGORVVVLJQLȴFDQWE\* ?67 ?&DQDO\VLV)'5qYDOXHVDQGWKHPRVWIUHTXHQWQRQVLJQLȴFDQWIRFDOUHJLRQRIJDLQDQGORVVLGHQWLȴHG
E\3&)VHJPHQWDWLRQDUHOLVWHG*HQHVORFDWHGLQWKHFRUUHVSRQGLQJUHJLRQDUHSUHVHQWHGWRWKHULJKW
aLGHQWLȴHGIURP(QVHPEOE ?GHQWLȴHGDOVRLQ(6FHOOOLQHV
&1$FRS\QXPEHUDEHUUDWLRQ
7DEOHɅRecurrent regions of loss in ES cell lines, showing loss in EC primary/cell lines.
Cytoband Cell line Start ES End ES
 
Segment size ES
Mean Log R 
ratio
Detected in EC 
cell lines
Detected in 
primary ECs
T + 242,915,466  119,220 −0.61   
H14 242,915,466   −0.49 2/5 1/13
Shef6 242,915,466   −0.49  
T +   9022 −1.46 2/5 5/13
Shef6   9022 −
T Shef6   39,650 −0.96 3/5 3/13
6KHI    −
T + 95,452,264   − 3/5 0/13
H14    −
S +    −1.12 4/5 4/13
H14    −1.34
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(4q21.21, 4q33-q34.1, 9q34.2, and 18q12.1), indicated as 
peaks in Fig. 1, and present in at least 9 of the 13 ECs 
(Table 3). Interestingly, a region on chromosome arm 9q 
showed frequent LOH but no copy number loss (Fig. 1), 
and is thus a copy neutral LOH.
'L ?HUHQWLDOO\H[SUHVVHGJHQHVDVVRFLDWHGZLWK'1$
FRS\QXPEHUOHYHOV
In a previous study, we identiied 28 differentially expressed 
genes between EC and ES cell lines (Alagaratnam  et  al. 
2013). The relative gene expression and the corresponding 
copy number changes from PCF for 27 genes (one was 
located on chromosome X) are shown for EC cell lines 
and tumours in Fig. 3. Six of the 16 genes with higher 
expression in EC compared to ES cell lines are localized 
on chromosome arm 12p (C12orf4, DPPA3, GOLT1B, 
NOP2, PARP11, and TULP3) and showed gain in all and 
ampliication in most EC cell lines (4/5) and primary 
ECs (9/13). However, the 10 remaining genes, and the 
11 genes with lower expression in EC compared to ES cell 
lines, were in regions with few CNAs.
 阀dHQWLȴFDWLRQRIWDUJHWJHQHVD ?HFWHGE\&1$V
Within the identiied regions of CNA or LOH in the 
EC subtype, there are several protein-coding genes of 
potential interest to EC development. There are 16 genes 
located in the GISTIC-deined focal loss or gain regions, 
ive genes within the ASCAT-deined LOH regions and in 
the two regions showing the most frequent aberrations 
(apart from 12p), as identiied by the PCF segmented data, 
there are three genes known to be cancer critical genes 
according to COSMIC. In addition, six genes previously 
identiied as differentially expressed between EC and ES 
cell lines were also found to be gained or ampliied in EC 
tumours. Taken together, we nominate 30 protein-coding 
genes affected by CNAs and/or LOH to be of interest to 
the EC subtype (Supplementary Table 2).
)LJXUHb
0LQLPDODPSOLFRQRINESRQFKURPRVRPH
DUPS&RS\QXPEHUDEHUUDWLRQVRQ
FKURPRVRPHIURPSULPDU\(&VSORWWHGE\
PHGLDQDGMXVWHGFRS\QXPEHUIURP$6&$7
DQDO\VLVDQGJHQRPLFSRVLWLRQ7RDOORZYLVLELOLW\
RIDOO'1$FRS\QXPEHUFKURPRVRPH
segments, for each tumour, the lines were 
DGMXVWHG6HJPHQWV0EDUHHQODUJHGDV
FLUFOHVWRLQFUHDVHWKHLUYLVLELOLW\
7DEOHɅ$OOHOHVSHFLȴF/2+LGHQWLȴHGLQSULPDU\(&V
Cytoband Samples with LOH Start ES End ES Segment size ES Genes in region
T 10   503,235 ANTXR2
TT 10   1,496,249 GALNTL6
T 9 136,642,066   BRD3, BRD3OS, VAV2
T 9    -
)RFDOUHJLRQVRI/2+LGHQWLȴHGE\$6&$7LQSULPDU\(&VZLWKFRUUHVSRQGLQJJHQHVORFDWHGLQWKHUHJLRQ
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'1$FRS\QXPEHUDQGP51$H[SUHVVLRQDPRQJ
7*&7VLQ7&*$GDWD
For further investigation of the genes affected by CNAs 
and/or LOH in ECs, we analysed copy number levels for 
27 of the 150 TGCT tumours from TCGA classiied as EC 
according to the ICD-O morphological codes (18 pure 
EC and 9 mixed). The genes identiied at 12p, including 
SLC2A3 and SLC2A14, were gained in all 27 samples 
and were highly ampliied in 8 of the samples (30%; 
Supplementary Fig. 5). ETV1, located at 7p21 was gained 
in 25 of the 27 samples, while CCDC6 and NCOA4 located 
at 10q11-q21 had copy number loss in 21 and 20 samples, 
respectively. Surprisingly, many of the genes located in 
focal regions identiied as statistically signiicant loss in 
our cohort by GISTIC, for example, 1q21.3, 1p36.11 and 
3q22.1, were infrequently lost in the EC cohort from 
TCGA (Supplementary Fig. 5).
A signiicant correlation (q < 0.05) between DNA 
copy number and mRNA expression data was seen 
for 15 of the 30 genes. These were ETV1 and CCDC6 
(from PCF-identiied gain/loss); LRP5L and SLC2A3  
(from GISTIC-identiied focal gain); TMEM50A and TRH 
(from GISTIC-identiied focal loss); ANTXR2, BRD3, 
BRD3OS, and VAV2 (from ASCAT-identiied LOH); C12orf4, 
DPPA3, GOLT1B, NOP2 and PARP11 (previously identiied 
as differentially expressed between EC and ES cell lines; 
Supplementary Fig. 5). Correlation between copy number 
and gene expression remained signiicant for four of the 
genes when only considering the EC subset (n = 27). This 
included a strong correlation for ETV1 (R = 0.8, q < 0.0001).
6RPDWLFPXWDWLRQVDPRQJ7*&7VLQ7&*$
TCGA whole-exome sequencing data were examined for 
somatic mutations in the 30 genes. We found that six of the 
150 TGCT samples contained markedly higher numbers 
of mutations genome-wide (median 1091.5 mutations), 
than the remaining TGCTs (median 38.5 mutations), and 
omitted these from further analysis. Among the included 
144 tumour samples, 20 (4/20 diagnosed as EC) were found 
to harbour somatic, non-synonymous mutations in 11 of 
the 30 genes (Supplementary Table 3). Non-synonymous 
mutations in two or more TGCTs were identiied in 
ANTXR2, LCE1F, SLC2A3, SLC2A14, and TULP3.
)XVLRQWUDQVFULSWEUHDNSRLQWVLQFOXGLQJWDUJHW 
JHQHVUHJLRQVDPRQJ7*&7VLQ7&*$
Next, we evaluated whether CNAs were associated 
with generation of fusion genes. After analysis of 
RNA-sequencing data from TCGA’s TGCT samples, 
the intersection of the outputs from two fusion inder 
software, FusionCatcher and deFuse, resulted in 1956 
nominated fusion transcript breakpoints (range 2 to 49 
per sample, median = 10). None of these transcript 
breakpoints involved the 30 genes affected by CNAs. 
However, when considering breakpoints of fusion 
transcripts within 1 Mbp of the identiied CNA segments, 
we detected the previously described CLEC6A-CLEC4D 
read-through fusion transcripts (Hoff  et  al. 2016) in 
12 of 150 TGCTs. Additionally, two fusion transcripts, 
LIN28A-CD52 and LRP6-LRRC23 were each detected in 
individual samples. Both these fusion transcripts were 
nominated with breakpoints joining the canonical 
exon-boundaries of the partner genes and are predicted 
to maintain reading frames (Table 4). These two fusion 
transcripts were however found to be predominantly 
expressed in the seminoma subtype of the TCGA 
samples (Table 4).
Interestingly, FusionCatcher and deFuse individually 
nominated a vast number of breakpoints involving 
)LJXUHb
'1$FRS\QXPEHUDOWHUDWLRQDQGJHQHH[SUHVVLRQLQ(&'1$FRS\
QXPEHUVWDWXVIRUGL ?HUHQWLDOO\H[SUHVVHGJHQHVnɋ ɋLQ(&FHOOOLQHV
YHUVXV(6FHOOOLQHVDVLGHQWLȴHGLQDSUHYLRXVVWXG\$ODJDUDWQDPbHWbDO. 
20137KHFRS\QXPEHUVWDWXVZDVGHWHUPLQHGE\3&)IRUȴYH(&FHOO
lines and 13 primary ECs. Thresholds applied: loss <-0.15; gain>0.15; 
DPSOLȴFDWLRQ!
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SLC2A3; 137 and 364, respectively. These breakpoints 
did not include the same partner genes in the 
individual samples and were therefore not considered 
in the intersected analysis. However, we observed that 
the number of breakpoints nominated per sample 
correlated between FusionCatcher and deFuse and 
that the nominated breakpoints were mostly in ECs 
and mixed germ cell tumours (16 and 15 out of in 
total 43, respectively; Supplementary Fig. 6). Overall in 
150 TGCTs, the correlation between gene expression and 
DNA copy numbers of SLC2A3 was signiicant (Spearman: 
R = 0.55, q = 9 × 10−12), whereas when only considering 
cases that had at least one nominated fusion breakpoint 
with SLC2A3 (n = 43), the correlation was not signiicant 
(Spearman: R = 0.26, P = 0.09).
'LVFXVVLRQ
We have here performed high-resolution DNA copy 
number analysis of the EC subtype of TGCT, and identiied 
broad and focal CNAs as well as allele-speciic CNAs, 
including LOH. We have nominated altogether 30 genes 
which may be related to EC within the regions affected by 
CNAs, including SLC2A3 from chromosome arm 12p and 
ETV1 on 7p21.
The CNA proiles varied in complexity among 
primary ECs. Both individual EC copy number proiles 
and the summarized overall CNA frequency plots, are 
in agreement with TGCT and EC proiles in particular 
(Kraggerud et al. 2002, Skotheim et al. 2006, Korkola et al. 
2008), however, in this study with higher resolution 
than previously reported. Previous studies of the copy 
number landscape of EC include two aCGH studies (n = 25 
(Korkola  et  al. 2008) and n = 32 (Gilbert  et  al. 2011)). 
Korkola et al. analysed several non-seminoma histological 
subtypes and did not ind a prominent separation of 
subtypes on the basis of DNA copy number proiling, 
as opposed to the gene expression-based classiication 
identiied earlier (Korkola et al. 2005). However, Korkola 
et al. reported EC-speciic genomic alterations at 1p33-31.2, 
2p25.3, and 17p11.2-q21.32 (Korkola et al. 2008). Gilbert 
et  al. proiled stage I ECs and identiied novel minimal 
regions of overlap of gain at 6p21.33, 10q11.21, and 
22q13.32, and of loss at 22q12.2. Our results are in 
agreement with alterations reported in these studies. 
However, apart from the common 12p gain and frequent 
7p gain, none of the signiicant, focal CNA identiied here 
were reported by Korkola  et  al. (2008) or Gilbert  et  al. 
(2011). To our knowledge, only one SNP microarray study 7D
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has been published, including 18 pure ECs and 9 mixed 
TGCTs with a dominant EC proportion of in total 137 
TGCTs (Shen  et  al. 2018). EC subtype-speciic CNAs are 
not reported in this TCGA study; however, they report that 
ECs’ CNA proiles cluster into three of ive identiied CNA 
groups. Among the focal, GISTIC-identiied alterations in 
the TGCT cohort of TCGA, gain at 12p12 is in agreement 
with our results.
(6DQG(&FHOOOLQHV
ES and EC cells have many common characteristics, and 
culture-adaptation of ES cells have been acknowledged 
as a model system for EC carcinogenesis (Andrews et al. 
2005). All seven ES cell lines included are previously 
analysed for CNAs on SNP microarrays (Närvä et al. 2010, 
Amps  et  al. 2011). Aberrations, identiied in individual 
cell lines at early passage were also found in our dataset, 
including gain at 2p11.2 and 3q26.1. A recurrent gain on 
20q11.21 in ES cell lines is suggested to confer a growth 
advantage (Amps  et  al. 2011). However, this gain is not 
found in the ES cell lines applied in our study. Also, 
none of the primary ECs showed gain of the 20q11.21 
region. Still, among EC cell lines, two showed gain and 
one a borderline gain, supporting that this CNA may 
be induced by cell culturing rather than relevant for EC 
tumourigenesis.
3ORLG\HVWLPDWHVRI(&V
Ploidy estimates by ASCAT showed that 9/13 (69%) 
of primary ECs were hyperdiploid to triploid, while 
4/13 (31%) were tetraploid to pentaploid. However, the 
algorithm gives an estimate of the on average ploidy and 
does not account for sub-clonality. This result is largely 
in agreement with previous studies, where ECs are often 
categorized as aneuploid or hypotriploid, and with low 
cytometry often several aneuploid cell population are 
observed (Fosså et al. 1991, Burger et al. 1994). The near 
triploidy among ECs has also been shown in cytogenetic 
studies (Sandberg et al. 1996).
+LJKOHYHODPSOLȴFDWLRQRIWKHJOXFRVHWUDQVSRUWHUV
SLC2A3 and SLC2A14LQ(&V
Gain of 12p was detected in all primary EC samples and EC 
cell lines, supporting its role as an early driver event in EC 
development. High-level ampliication of 12p segments 
has been reported in TGCT (Kraggerud  et  al. 2002, 
Skotheim et al. 2006), mostly focusing on a 12p11.2-p12.1 
amplicon (Bourdon  et  al. 2002, Zafarana  et  al. 2003). 
Interestingly, we identiied two novel segments with focal 
ampliication; a 3.5 Mbp segment on 12p11.1 with no 
annotated genes, and a 100 kbp segment on 12p13.31. The 
latter segment corresponds to minimal amplicons present 
at estimated 15 and 31 additional copies in two individual 
ECs. This segment overlaps with both a larger region of 
ampliication at 12p13 identiied in a CGH study of TGCT 
cell lines (Henegariu  et  al. 2004) and a 200 kbp region/
gene cluster at 12p13.31 that exhibits coordinated over-
expression in both ECs and seminomas (Korkola  et  al. 
2006). The small, 100 kbp ampliied region contains two 
glucose transporter genes, SLC2A3 and parts of SLC2A14.
Increased SLC2A3 expression is reported in TGCTs 
compared to normal testis (Rodriguez  et  al. 2003), and 
validated as a sensitive and speciic marker for the EC and 
yolk sac tumour histological subtypes (Howitt et al. 2013). 
In vitro differentiation of EC cells, with subsequent loss 
of tumourigenic potential, is reported to repress several 
pluripotency genes at this locus, including NANOG, 
GDF3, and DPPA3, but also SLC2A3 (Giuliano  et  al. 
2005). SLC2A14 is a paralog of SLC2A3 and with major 
expression in testis. We showed in data from TCGA, that 
the expression signiicantly correlates with copy number 
gains for SLC2A3, but not for SLC2A14. These results 
imply that ampliication and over-expression of SLC2A3 
may be a common mechanism for activation. SLC2A3 
and SLC2A14 were among the most frequently mutated 
of the investigated target genes (each observed with 
somatic mutation in three TCGA TGCTs, where one had 
an EC component). A large number of fusion transcript 
breakpoints were nominated for SLC2A3. Interestingly, 
expression of SLC2A3 and DNA copy number did not 
correlate signiicantly for the samples that had nominated 
SLC2A3 fusion breakpoints, which indicates that 
overexpression of SLC2A3 in these cases is regulated by 
other mechanisms than the number of gene copies alone.
The roles of SLC2A14 and SLC2A3 in cancer have 
more recently gained attention. SLC2A14 (or GLUT14) 
expression is deregulated in several cancer types and 
is suggested to be a prognostic factor for a number of 
cancers, for example, in thyroid carcinoma (Chai  et  al. 
2017). SLC2A3 (alias GLUT3) encodes a glucose 
transporter with a ive-fold higher afinity for glucose 
than its ubiquitous family member GLUT1 (Simpson et al. 
2008), making its expression an advantage in glucose-
poor microenvironments with high glucose demands, 
such as in certain tumour environments. Indeed, SLC2A3 
expression correlates with poor survival in several cancers, 
including brain and gastric cancers (Flavahan et al. 2013, 
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Schlößer  et  al. 2017). While broad level gain of 12p in 
TGCTs appears likely to confer the pluripotent phenotype 
for initiation of tumourigenesis, the focal ampliication of 
the region containing SLC2A3 may grant a proliferative 
advantage in progression and development of the tumour.
&1$VDWSDQGTD ?HFWWKHFDQFHUFULWLFDOJHQHV
ETV1 and CCDC6
The second most frequently gained (after 12p) and the 
most frequently lost regions in ECs were located at 7p 
and at 10q, respectively. Among the genes located in 
these regions, ETV1, CCDC6, and NCOA4 are known 
cancer critical genes. Several previous studies indicate 
that the functions of these genes are relevant in respect 
to TGCT development. Activated KIT is reported to 
prolong ETV1 protein stability and cooperate with ETV1 
to promote tumorigenesis in gastrointestinal tumours 
(Chi  et  al. 2010). Disruption of the KIT–KITLG/MAPK 
signalling pathway is implicated in TGCT formation both 
as a predisposing germline risk factor and somatic driver 
event (Litchield et al. 2015, 2017). ETV1 has been shown 
to upregulate the expression of androgen receptor target 
genes and promote autonomous testosterone production 
(Baena et al. 2013).
CCDC6 is a tumour-suppressor and a pro-apoptotic 
protein involved in DNA damage response and repair 
(Merolla et al. 2012). Loss of CCDC6 has been suggested to 
contribute to testicular neoplastic growth (Staibano et al. 
2013) and could enhance tumour progression by 
impairing apoptosis following DNA damage (Cerrato et al. 
2018). In effect, loss of CCDC6 has also been implicated 
as a biomarker to sensitizing cancer cells to treatment 
with PARP inhibitors (Cerrato et al. 2018).
)XVLRQJHQHVORFDWHGRQFKURPRVRPHDUPS
We have previously identiied novel fusion transcripts 
in TGCT (Hoff  et  al. 2016). In this study we analysed 
RNA sequencing data of TGCTs from the TCGA for the 
expression of fusion transcripts in proximity (1 Mbp) of 
identiied regions of gain, loss, and LOH. We reasoned 
that CNAs may relect structural rearrangements that 
form fusion genes. We repeatedly identiied the fusion 
event CLEC6A-CLEC4D (n = 12 patients) and also two 
private fusion events, LIN28A-CD52 and LRP6-LRRC23. 
These fusions were, however, found expressed in non-EC 
histological subtypes (Table 4). Both genes involved in the 
CLEC6A-CLEC4D and the LRP6-LRRC23 fusion genes are 
located on chromosome arm 12p. Previously, we described 
several other private fusion genes on 12p (Hoff  et  al. 
2016). The recurrent structural alterations of 12p may be 
a common mechanism for the generation and expression 
of fusion genes in TGCT. However, the biological impact 
of these mostly private fusion gene events is uncertain.
In conclusion, by use of high-resolution SNP 
microarrays and advanced analyses, we present allele-
speciic copy number proiles for primary ECs and several 
novel focal CNAs. Within the regions affected by CNAs, 
we report 30 target genes that may be of interest to further 
our understanding of the EC subtype. High ampliication 
of a 100 kbp segment at 12p13.31 containing SLC2A3 
was identiied and the second most common CNA 
identiied as gain at 7p21 encompassed the cancer critical 
gene ETV1. Increasing DNA copy numbers were found 
to be correlated with increased gene expression of SLC2A3 
and ETV1.
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